Warts in cattle are caused by bovine papillomaviruses. While there are many different types of bovine papillomaviruses, the most common is called bovine papillomavirus 1 (BPV L1).
Historically, wart vaccines have been crude tissue homogenates that raise concerns about safety as well as inconsistent availability.
Our bovine wart vaccine is produced using a baculovirus that is engineered to expresses the main surface protein of BPV L1. This recombinant bovine papillomavirus protein naturally self-assembles into virus-like particles that are antigenically indistinguishable from natural BPV L1.
The inactivated baculovirus culture containing BPV L1 virus-like particles is adjuvanted with our proprietary PS50 oil-in-water adjuvant to help stimulate a robust humoral immune response following subcutaneous administration.
The vaccine stimulates the bovine immune system to generate neutralizing antibodies, which are a demonstrated correlate of protection to fibropapillomas. Trials in cattle have demonstrated high neutralizing titers in calves following administration of our vaccine, which led to complete protection from the development of warts following challenge.
